Mohammad Amjad Kamal

Prof. Dr Mohammad Amjad Kamal is a distinguished scientist and leads his global research team. His extensive contributions to biochemistry research have resulted in over 700 publications in internationally renowned journals and 65 abstracts presented at international conferences. Notably, his work played a pivotal role in the development of novel anti-Alzheimer agents, transitioning them from the laboratory to clinical trials in collaboration with Dr Nigel H. Greig, Chief of the Laboratory of Neurosciences at the National Institutes of Health (NIH), USA. In 1998, Prof. Kamal migrated to Australia and was awarded the prestigious U2000 Postdoctoral Fellowship by the University of Sydney's School of Molecular and Microbial Biosciences in 2000. This highly competitive three-year fellowship funded his research on the “Inhibition of amido phosphoribosyl transferase by new antifolates: Design and mechanism of action of purine antagonists.” He also collaborated on a molecular biology research project addressing Type 2 diabetes and Alzheimer’s disease at the University of Technology Sydney. In 2011, Prof. Kamal established the "Fundamental and Applied Biology Group" and the "Metabolomics & Enzymology Unit" at King Fahd Medical Research Center (KFMRC). His efforts were focused on advancing scientific research and delivering translational health services, particularly benefiting the local Arab community. During his tenure, he served as Coordinator of the KFMRC Publication Committee and was appointed as a scientific member of the Chair for "Yousef Abdul Latif Jameel Therapeutic Applications in the Prophet's Medicine." Prof. Kamal is an active member of editorial boards and serves as a guest editor for several esteemed journals. His academic and research endeavours have taken him across the globe, enriching his multicultural perspective. This global experience enhances his role as a Visiting Professor at King Faisal University. He also previously held a position at West China Hospital, Sichuan University, China etc..